These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34409517)

  • 1. Effectiveness of dual migraine therapy with CGRP inhibitors and onabotulinumtoxinA injections: case series.
    Toni T; Tamanaha R; Newman B; Liang Y; Lee J; Carrazana E; Vajjala V; Viereck J; Liow KK
    Neurol Sci; 2021 Dec; 42(12):5373-5376. PubMed ID: 34409517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence to anti-CGRP monoclonal antibodies and onabotulinumtoxinA among patients with migraine: a retrospective cohort study.
    Charleston L; Talon B; Sullivan C; Anderson C; Kymes S; Regnier SA; Soni-Brahmbhatt S; Nahas SJ
    J Headache Pain; 2023 Aug; 24(1):101. PubMed ID: 37532991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.
    Mechtler L; Saikali N; McVige J; Hughes O; Traut A; Adams AM
    Front Neurol; 2021; 12():788159. PubMed ID: 35069416
    [No Abstract]   [Full Text] [Related]  

  • 4. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.
    Iannone LF; Fattori D; Marangoni M; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
    CNS Drugs; 2023 Feb; 37(2):189-202. PubMed ID: 36656298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review.
    Blumenfeld AM; Frishberg BM; Schim JD; Iannone A; Schneider G; Yedigarova L; Manack Adams A
    Pain Ther; 2021 Dec; 10(2):809-826. PubMed ID: 33880725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study.
    Grazzi L; Giossi R; Montisano DA; Canella M; Marcosano M; Altamura C; Vernieri F
    J Headache Pain; 2024 Feb; 25(1):14. PubMed ID: 38308209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine.
    Berman G; Croop R; Kudrow D; Halverson P; Lovegren M; Thiry AC; Conway CM; Coric V; Lipton RB
    Headache; 2020 Sep; 60(8):1734-1742. PubMed ID: 32799325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.
    Schoenen J; Manise M; Nonis R; Gérard P; Timmermans G
    Rev Neurol (Paris); 2020 Dec; 176(10):788-803. PubMed ID: 32758365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine.
    Cohen F; Armand C; Lipton RB; Vollbracht S
    Pain Med; 2021 Aug; 22(8):1857-1863. PubMed ID: 33693863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
    Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alopecia signals associated with calcitonin gene-related peptide inhibitors in the treatment or prophylaxis of migraine: A pharmacovigilance study.
    Woods RH
    Pharmacotherapy; 2022 Oct; 42(10):758-767. PubMed ID: 35975575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.
    Scheffler A; Schenk H; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Holle D
    J Headache Pain; 2021 Sep; 22(1):111. PubMed ID: 34544359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
    Talbot J; Stuckey R; Crawford L; Weatherby S; Mullin S
    J Headache Pain; 2021 Jan; 22(1):5. PubMed ID: 33421995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA Add-On to Monoclonal Anti-CGRP Antibodies in Treatment-Refractory Chronic Migraine.
    Argyriou AA; Dermitzakis EV; Xiromerisiou G; Vikelis M
    Toxins (Basel); 2022 Dec; 14(12):. PubMed ID: 36548744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual therapy with Erenumab and onabotulinumtoxinA: No synergistic effect in chronic migraine: A retrospective cohort study.
    Jaimes A; Gómez A; Pajares O; Rodríguez-Vico J
    Pain Pract; 2023 Apr; 23(4):349-358. PubMed ID: 36507609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
    Henson B; Hollingsworth H; Nevois E; Herndon C
    J Pain Palliat Care Pharmacother; 2020 Mar; 34(1):22-31. PubMed ID: 31763951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies.
    Ailani J; Pearlman E; Zhang Q; Nagy AJ; Schuh K; Aurora SK
    Eur J Neurol; 2020 Mar; 27(3):542-549. PubMed ID: 31595600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.